AGP Executive Report
Last update: 2 hours agoRare Disease Update: Rocket Pharmaceuticals (Cranbury) says early safety looks promising in its modified Phase 2 RP-A501 trial for Danon disease, with no thrombotic microangiopathy or capillary leak seen in the first three treated patients, and it’s now aligning with the FDA on next dosing steps. Health Tech Security: CareCloud has started notifying about 345,000 people after hackers accessed an electronic health record system, potentially exposing medical, financial, and identity data. Cancer Care Access: FDA approval expands eligibility for Novartis’ Pluvicto prostate cancer radioligand therapy, but access still depends on licensed centers that can administer the radioactive treatment. M&A Watch: Curium and Lantheus announced a definitive merger agreement (up to $8B value), aiming to combine radiopharmaceutical theranostics with Lantheus’ radiodiagnostics business. NJ Environment & Health: BioLargo reports its PFAS remediation system at Lake Stockholm, NJ has treated more than 2 million gallons over six months, with ongoing NJDEP/EPA monitoring. Legal/Policy: New Jersey and New York are suing to block Trump administration changes to ACA health insurance marketplaces.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
